Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2025 AANEM Annual Meeting

NEW YORK and WALTHAM, Mass., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced that the results of the Phase 2 MaGic trial of claseprubart in generalized Myasthenia Gravis (gMG) will be presented in an oral presentation at the American Association of Neuromuscular and Electromagnetic Medicine (AANEM) Annual Meeting, taking place October 29 to November 1, 2025 in San Francisco, California. In addition, the Company will host a virtual industry forum on October 29 titled Upstream Targeting: Rethinking MG Treatment Through Active C1s Inhibition.

Read more at globenewswire.com